ArticleAmerican journal of human genetics2026
Newborn screening for type 1 diabetes using genome-based risk scores in the Early Check program.
Article in American journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Type 1 diabetes (T1D) is an autoimmune disease that often presents in childhood and can lead to life-threatening complications such as diabetic ketoacidosis. Genetic risk scores (GRSs) offer an innovative approach to early identification of T1D risk, but their integration into newborn screening (NBS) has not been implemented at scale in the United States. We evaluated the feasibility of using whole-genome sequencing (WGS) of dried blood spot samples to calculate and return T1D GRSs within a real-world screening program. Early Check is a statewide voluntary NBS research program in North Carolina. Between September 2023 and June 2024, 2,125 newborns were enrolled for WGS-based screening, including optional GRS-based T1D screening. Predicted T1D risk was calculated using a validated pipeline based on the previously developed 67-variant T1D GRS2 model. Results were returned to parents via a secure portal, and newborns with elevated genetic risk were offered islet autoantibody testing. Of the 1,742 newborns whose parents elected T1D screening, 1,603 (92%) received a valid GRS2 result. Sixty-two (3.9%) were classified as higher concern and 118 (7.4%) as moderate concern. Among the higher-concern group, 41 initiated autoantibody testing at 9 months, with two testing positive; both reverted to negative at 12 months. GRS2 scores were lower in African ancestry newborns, highlighting the need for ancestry-specific thresholds or models. T1D GRS screening is feasible in a population NBS using WGS. Results support its potential for early-life risk stratification while underscoring the need for improved cross-ancestry performance and long-term validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.